医学影像技术企业Imagion Biosystems（ASX: IBX）已正式向美国食品药品监督管理局（FDA）提交新药临床试验申请（IND），计划开展其旗舰产品Magsense® Her2靶向显影剂的二期临床试验。该显影剂采用创新纳米技术，旨在通过高精度磁共振成像实现对HER2阳性肿瘤的早期识别与定位，为乳腺癌等癌症的精准诊疗提供新方案。此次IND获批后将启动多中心临床研究，进一步验证该显影剂的安全性与成像效能，有望填补现有HER2检测技术的可视化诊断空白。
医学影像技术企业Imagion Biosystems（ASX: IBX）已正式向美国食品药品监督管理局（FDA）提交新药临床试验申请（IND），计划开展其旗舰产品Magsense® Her2靶向显影剂的二期临床试验。该显影剂采用创新纳米技术，旨在通过高精度磁共振成像实现对HER2阳性肿瘤的早期识别与定位，为乳腺癌等癌症的精准诊疗提供新方案。此次IND获批后将启动多中心临床研究，进一步验证该显影剂的安全性与成像效能，有望填补现有HER2检测技术的可视化诊断空白。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.